JP5786178B2 - Ttkペプチドおよびそれを含むワクチン - Google Patents

Ttkペプチドおよびそれを含むワクチン Download PDF

Info

Publication number
JP5786178B2
JP5786178B2 JP2011548451A JP2011548451A JP5786178B2 JP 5786178 B2 JP5786178 B2 JP 5786178B2 JP 2011548451 A JP2011548451 A JP 2011548451A JP 2011548451 A JP2011548451 A JP 2011548451A JP 5786178 B2 JP5786178 B2 JP 5786178B2
Authority
JP
Japan
Prior art keywords
peptide
cancer
ttk
ctl
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011548451A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012526519A (ja
JP2012526519A5 (https=
Inventor
中村 祐輔
祐輔 中村
卓也 角田
卓也 角田
龍司 大沢
龍司 大沢
祥子 吉村
祥子 吉村
朝久 渡辺
朝久 渡辺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JP2012526519A publication Critical patent/JP2012526519A/ja
Publication of JP2012526519A5 publication Critical patent/JP2012526519A5/ja
Application granted granted Critical
Publication of JP5786178B2 publication Critical patent/JP5786178B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011548451A 2009-05-11 2010-05-10 Ttkペプチドおよびそれを含むワクチン Expired - Fee Related JP5786178B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21601709P 2009-05-11 2009-05-11
US61/216,017 2009-05-11
PCT/JP2010/003166 WO2010131452A1 (en) 2009-05-11 2010-05-10 Ttk peptides and vaccines including the same

Publications (3)

Publication Number Publication Date
JP2012526519A JP2012526519A (ja) 2012-11-01
JP2012526519A5 JP2012526519A5 (https=) 2013-06-27
JP5786178B2 true JP5786178B2 (ja) 2015-09-30

Family

ID=43084837

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011548451A Expired - Fee Related JP5786178B2 (ja) 2009-05-11 2010-05-10 Ttkペプチドおよびそれを含むワクチン

Country Status (13)

Country Link
US (1) US8530430B2 (https=)
EP (1) EP2430039A4 (https=)
JP (1) JP5786178B2 (https=)
KR (1) KR20120029394A (https=)
CN (1) CN102459314B (https=)
AU (1) AU2010248702A1 (https=)
BR (1) BRPI1013938A2 (https=)
CA (1) CA2761393A1 (https=)
MX (1) MX2011012013A (https=)
RU (1) RU2531348C2 (https=)
SG (1) SG175998A1 (https=)
TW (1) TW201102081A (https=)
WO (1) WO2010131452A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2873155C (en) 2012-09-11 2022-07-26 Oncotherapy Science, Inc. Ube2t peptides and vaccines containing the same
WO2018090257A1 (zh) * 2016-11-16 2018-05-24 深圳华大基因研究院 多肽及其应用
WO2018098636A1 (zh) * 2016-11-29 2018-06-07 深圳华大基因研究院 多肽及其应用
FI3652606T3 (fi) * 2017-07-12 2023-03-16 Nouscom Ag Jaettuihin tuumorineoantigeeneihin perustuva yleisrokote epästabiilien mikrosatelliitti (msi) -syöpien ennaltaehkäisyyn ja hoitoon
CN120712104A (zh) * 2022-10-14 2025-09-26 广东天科雅生物医药科技有限公司 针对神经胶质瘤的肽疫苗及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187548B1 (en) * 1993-05-23 2001-02-13 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods using human calcium sensor protein, fragments thereof and DNA encoding same
US20030045491A1 (en) 2001-02-23 2003-03-06 Christoph Reinhard TTK in diagnosis and as a therapeutic target in cancer
US7501243B2 (en) * 2001-02-21 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Detection of colon or breast cancer by measuring TTK polypeptide expression
KR100876327B1 (ko) 2001-02-21 2008-12-31 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 진단에서의, 그리고 암에서 치료 표적으로서의 ttk
AU2002309583A1 (en) 2001-04-18 2002-11-05 Protein Desing Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2003210393A1 (en) * 2002-02-27 2003-09-09 Michael Rik Frans Brands A data integration and knowledge management solution
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
DE602004015064D1 (de) 2003-01-06 2008-08-28 Wyeth Corp Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
WO2004070062A2 (en) 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
WO2004094636A1 (en) 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs
EP1670955A2 (en) 2003-09-22 2006-06-21 Rosetta Inpharmatics LLC. Synthetic lethal screen using rna interference
JP4721903B2 (ja) * 2004-01-29 2011-07-13 大日本住友製薬株式会社 新規腫瘍抗原蛋白質及びその利用
GB0426393D0 (en) 2004-12-01 2005-01-05 Cancer Rec Tech Ltd Materials and methods relating to modulators of spindle checkpoint kinases
CN102747140A (zh) 2004-12-08 2012-10-24 安万特药物公司 测量对多西他赛抗药性或敏感性的方法
CN101175862A (zh) 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
ES2364670T3 (es) * 2005-02-25 2011-09-12 Oncotherapy Science, Inc. Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos ttk.
EP2295570A1 (en) 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
EP2311985A1 (en) 2005-07-27 2011-04-20 Oncotherapy Science, Inc. Sirna for treating esophageal cancer
EP2102360A2 (en) 2006-12-13 2009-09-23 Oncotherapy Science, Inc. Ttk as tumor marker and therapeutic target for lung cancer
TWI596109B (zh) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
US8492356B2 (en) 2007-12-21 2013-07-23 University Health Network Methods of inhibiting tumor growth using TTK antagonists
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Also Published As

Publication number Publication date
EP2430039A1 (en) 2012-03-21
KR20120029394A (ko) 2012-03-26
CN102459314A (zh) 2012-05-16
WO2010131452A1 (en) 2010-11-18
EP2430039A4 (en) 2012-12-05
JP2012526519A (ja) 2012-11-01
CA2761393A1 (en) 2010-11-18
SG175998A1 (en) 2011-12-29
RU2011150283A (ru) 2013-06-20
BRPI1013938A2 (pt) 2019-09-24
MX2011012013A (es) 2012-02-23
US8530430B2 (en) 2013-09-10
AU2010248702A1 (en) 2011-11-17
TW201102081A (en) 2011-01-16
US20120135020A1 (en) 2012-05-31
CN102459314B (zh) 2016-01-20
RU2531348C2 (ru) 2014-10-20

Similar Documents

Publication Publication Date Title
JP6349560B2 (ja) Topkペプチドおよびそれを含むワクチン
JP6295491B2 (ja) Kntc2ペプチドおよびそれを含むワクチン
JP5799394B2 (ja) Neil3ペプチドおよびそれを含むワクチン
JP5884104B2 (ja) 改変melkペプチドおよびそれを含むワクチン
JP2013523084A (ja) Cdca5ペプチドおよびそれを含むワクチン
JP6283861B2 (ja) Ube2tペプチドおよびそれを含むワクチン
JP5564730B2 (ja) Mphosph1ペプチドおよびそれを含むワクチン
JP2014519311A (ja) Sema5bペプチドおよびそれを含むワクチン
JP5786178B2 (ja) Ttkペプチドおよびそれを含むワクチン
JP2016222676A (ja) Tomm34ペプチドおよびそれを含むワクチン
JP2012519470A (ja) Vangl1ペプチドおよびそれを含むワクチン
JP5838482B2 (ja) Hjurpペプチドおよびそれを含むワクチン
JP5816965B2 (ja) Ect2ペプチドおよびそれを含むワクチン
JP5728759B2 (ja) C6orf167ペプチドおよびそれを含むワクチン
WO2012032764A1 (en) Ttll4 peptides and vaccines containing the same
JP2013513549A (ja) Tmem22ペプチドおよびそれを含むワクチン
JP2013512659A (ja) Mybl2ペプチドおよびそれを含むワクチン
JP2016502499A (ja) Sema5bペプチドおよびそれを含むワクチン
JP2014500001A (ja) C18orf54ペプチドおよびそれを含むワクチン
JP2014504146A (ja) Wdhd1ペプチドおよびそれを含むワクチン
JP2013523083A (ja) Cluap1ペプチドおよびそれを含むワクチン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141113

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150317

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150623

R150 Certificate of patent or registration of utility model

Ref document number: 5786178

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees